Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

p> Marketing, general

and administrative 11,198 11,170 2,400 2,945

Total operating

expenses 46,062 42,220 10,164 10,625

Interest income 1,786 2,648 363 644

Interest expense (1,053) (834) (281) (191)

Other expense (66) (105) (66) (76)

Change in valuation of

warrants 2,314 - 2,314 -

Total other income

(expense), net 2,981 1,709 2,330 377

Net loss $(43,081) $(40,511) $(7,834) $(10,248)

Historical net

loss per share:

Basic and diluted $(1.28) $(1.49) $(0.21) $(0.35)

Weighted-average

shares -

basic and

diluted 33,581,590 27,247,385 38,112,063 28,931,495

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF CASH FLOWS

(in thousands)

Years ended December 31,

2007 2006

(unaudited)

Operating activities:

Net loss $(43,081) $(40,511)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 3,449 2,133

Stock-based compensation 4,584 4,010

Amortization of premium/discount on short-term

investments (412) (638)

Change in valuation of warrants (2,314) -

Other
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email: